Healthcare Business

NanoViricides made another stride in the fight against COVID-19, and investors have to be happy about it.
Pfizer is among the current frontrunners for a COVID-19 vaccine, so why is its stock down 13% year to date? And why does one independent research firm say this stock could run much higher?
After Corvus Pharmaceuticals announced that it would initiate an early-stage immunotherapy study in patients with COVID-19, Wedush sees this stock running much higher.
Biogen may be on track to be one of the first companies with a meaningful treatment for Alzheimer’s disease, and this could have huge implications for the stock.
Many hospitals shut down elective surgeries and other activities to brace for the impact of COVID-19. However, analysis on these shutdowns is yielding some interesting insight.
A new research report outlines favorable Liquidia Technologies drug study data that will be presented in the coming weeks, which could add up to more than 300% potential upside.
Corvus Pharmaceuticals watched the COVID-19 stock bump play out in Tuesday’s session as this company joins the ever-growing list of coronavirus stocks.
Novavax and Regeneron Pharmaceuticals each made solid progress on Tuesday after each company received a sizable capital injection from the U.S. government’s Operation Warp Speed program.
24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a big push as 2020 continues.
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Akero Therapeutics has been public for only about a year now, and despite shares surging over 30% to an all-time high in Wednesday’s session, analysts think this stock can go much higher.
Some small companies are destined to be small forever. Others can grow into huge companies over time. What will be the story for Aytu BioScience?
Pfizer and BioNTech have been collaborating to produce a messenger RNA based vaccine for the past few months, and this work is yielding promising results.
T2 Biosystems solidified its position as a coronavirus stock on Wednesday morning when it announced the launch of its COVID-19 molecular diagnostic test.
While COVID-19 pandemic is not its only target, that has been the main driver of the interest in Inovio Pharmaceuticals so far in 2020.